Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Yugo Kai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3749-1360; OpenAlex author ID A5012628849. Sources: OpenAlex.

Their work

Papers
20
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2021: 2 papers · 2022: 5 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers · 2026: 5 papers

Papers 20

  1. Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment. Co-author DOI 10.1002/cnr2.70492↗
  2. Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic C… Co-author DOI 10.1002/cnr2.70691↗
  3. Effects of Pancreatic Duct Stenting on Nutrition and Pancreatic Function in Unresectable Pancreatic Cancer: A Pilot Study. Co-author DOI 10.1002/jgh3.70358↗
  4. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Co-author DOI 10.1007/s10147-026-03071-6↗
  5. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
  6. Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01309-6↗
  7. Impact of zinc deficiency on the prognosis of unresectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.007↗
  8. Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. Co-author DOI 10.1007/s10147-024-02544-w↗
  9. Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-024-73020-8↗
  10. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. Co-author DOI 10.1186/s12885-024-12722-8↗
  11. Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. Co-author DOI 10.1007/s00432-023-04966-x↗
  12. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. Co-author DOI 10.1186/s12885-023-11205-6↗
  13. Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Co-author DOI 10.3390/cancers15030970↗
  14. Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. Co-author DOI 10.1016/j.jgo.2022.07.010↗
  15. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  16. Refractory Lower Limb Edema Resolved by Endovascular Stent Placement for Inferior Vena Cava Stenosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002152↗
  17. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… Co-author DOI 10.1371/journal.pone.0264653↗
  18. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… Co-author DOI 10.3390/curroncol29040216↗
  19. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastat… Co-author DOI 10.1002/jgh3.12555↗
  20. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Ikezawa · 20 shared papers, 2021–2026 · strength 3.65
  2. Ryoji Takada · 20 shared papers, 2021–2026 · strength 3.65
  3. Kazuyoshi Ohkawa · 20 shared papers, 2021–2026 · strength 3.65
  4. Makiko Urabe · 17 shared papers, 2021–2026 · strength 3.25
  5. Takuo Yamai · 14 shared papers, 2021–2026 · strength 2.20
  6. Ko Watsuji · 7 shared papers, 2023–2026 · strength 1.34
  7. Yusuke Seiki · 7 shared papers, 2023–2026 · strength 1.34
  8. Kana Hosokawa · 4 shared papers, 2025–2026 · strength 0.96
  9. Yasuharu Kawamoto · 6 shared papers, 2022–2024 · strength 0.92
  10. Kazuma Daiku · 6 shared papers, 2021–2022 · strength 0.79
  11. Nobuyasu Fukutake · 5 shared papers, 2021–2026 · strength 0.76
  12. Hidenori Takahashi · 4 shared papers, 2021–2026 · strength 0.73
  13. Takumi Kinomoto · 3 shared papers, 2025–2026 · strength 0.71
  14. Shigenori Nagata · 3 shared papers, 2022–2026 · strength 0.56
  15. Yoji Kukita · 2 shared papers, 2023–2026 · strength 0.39
  16. Shinichiro Hasegawa · 2 shared papers, 2022–2026 · strength 0.38
  17. Hisataka Ogawa · 2 shared papers, 2022–2026 · strength 0.38
  18. Tomoya Ekawa · 2 shared papers, 2022–2026 · strength 0.38
  19. Hideaki Tahara · 2 shared papers, 2022–2026 · strength 0.38
  20. Hirofumi Akita · 2 shared papers, 2021–2026 · strength 0.35
  21. Kunihito Gotoh · 1 shared paper, 2026 · strength 0.24
  22. Reiko Ashida · 2 shared papers, 2021 · strength 0.22
  23. Teruki Teshima · 1 shared paper, 2021 · strength 0.11
  24. Kazuhiro Katayama · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.